SMITH-MAGENIS SYNDROME AND ITS CIRCADIAN INFLUENCE ON DEVELOPMENT, BEHAVIOR, AND OBESITY – OWN EXPERIENCE*

Li Chen¹, Sureni V. Mullegama², Joseph T. Alaimo², Sarah H. Elsea²

¹Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
²Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA

Abstract
Smith-Magenis syndrome (SMS) is a complex genetic disorder characterized by sleep disturbance, multiple developmental anomalies, psychiatric behavior, and obesity. It is caused by a heterozygous 17p11.2 microdeletion containing the retinoic acid-induced 1 (RAI1) gene or mutation within RAI1. Sleep disorder is one of the most penetrant features of SMS. Molecular genetic studies indicate that RAI1 regulates circadian rhythm genes and when haploinsufficient, causes a distorted molecular circadian network that may be the cause of the sleep disturbance and the inverted rhythm of melatonin present in most individuals with SMS. RAI1 also regulates genes involved in development, neurobehavior, and lipid metabolism. Sleep debt, daytime melatonin secretion, and environmental stress often contribute to negative behavior in persons with SMS, and food entrained circadian rhythm also influences food intake behavior and humoral signals, which also affect development and neurobehavior. The cross-talk between circadian rhythm, development, metabolism and behaviors affect the multiple phenotypic outcomes in Smith-Magenis syndrome. These findings shed light on possible effective and personalized drug treatments for SMS patients in the future.

Key words: melatonin, RAI1, CLOCK, BDNF, intellectual disability, 17p11.2 deletion

1. PHENOTYPIC FEATURES AND MOLECULAR GENETICS OF SMS
Smith-Magenis syndrome (SMS) is a complex neurobehavioral disorder with an estimated prevalence of 1:15,000 to 1:25,000 live births [1]. Characteristic SMS features include sleep abnormalities (Figure 1A), craniofacial (Figure 1B) and skeletal anomalies, intellectual disability, self-injurious behaviors (Figure 1C), stereotypical behavior (Figure 1D), metabolic problems and obesity (Figure 1E) [2]. A more detailed clinical phenotypic spectrum of SMS catalog in sleeping disorder, developmental anomalies, neurological and behavior problems, and obesity is listed in Table I.

Molecular cytogenetic analyses of SMS patients show a common deletion in ~70% of individuals that spans ~3.8 Mb and contains 76 genes in chromosome band 17p11.2 [1, 3]. Within this region lies RAI1, the primary causative gene [4]. RAI1 spans ~130 kb and contains six exons, including 4 coding exons which encode a 1906 amino acid protein. Rai1 was first identified as a gene (designated Gt1) induced by retinoic acid in P19 mouse embryonic carcinoma cells [5]. It is localized in the nucleus and is expressed in migrating neural crest cells and the nervous system early in development, and also, at lower levels, in adult brain [6]. It functions as a transcriptional regulator with a PHD (plant homeodomain) motif [7] and acts as a “histone reader,” bridging specific histone modifications and other transcription factors [8].

About 90% of SMS patients carry a 17p11.2 deletion containing RAI1 [3], with the remaining 10% of individuals harboring mutations within the gene, including insertions or deletions within the coding region that result in frameshifts and truncated proteins, as well as missense and nonsense mutations [7, 9-11]. All reported mutations to date lie within the coding region of exon 3, which represents

---

¹This work was supported by Smith-Magenis Syndrome Research Foundation (SHE, SVM), National Science Foundation-China (NSFC) grant 31200937 (LC), and Shanghai Health and Family Planning Commission grant 20144Y0106 (LC).
of SMS [18] and includes difficulties in falling asleep at daytime napping [18-21].

sleep, early waking, frequent night-time arousals, and night, reduced or absent rapid eye movement (REM) for these major phenotypes [3].

mutations, indicating that RAI1 is the key gene accounting features are consistent in all SMS patients, including both with RAI1 mutation [3]. This suggests the presence of other genetic contributors to SMS phenotype spectrum. Data show that phenotypes like loss (MYO15A) [17]. These genes further complicating the 17p11.2 deletion rather than with RAI1 mutation [3]. This COP9 complex encoded by COPS3 is related to 26S proteasome and cardiovascular anomalies are more associated with short stature, hearing loss, speech and motor delay, hypotonia SMS phenotypic spectrum. Data show that phenotypes like loss (MYO15A) [17]. These genes further complicating the anomalies can include midface hypoplasia and tented upper lip in SMS; C. Self-injurious behaviors like pulling out of fingernails and/or toenails are unique to SMS; D. Stereotypical behavior like self-hugging in SMS patient, typically observed during times of excitement or happiness; E. Obesity is frequently observed in persons with SMS.

approximately 95% of the coding sequence of this gene. A mutation hotspot region in exon 3 has been identified for causing frameshifts within RAI1 [10].

Studies have shown that variability and severity in SMS are modified by other genes in the common deletion region [3, 12, 13]. For example, indirect evidence links subunit 3 of the COP9 complex (COPS3) with melatonin metabolism. The COP9 complex encoded by COPS3 is related to 26S proteasome regulatory complex, which has been associated with control of the rate-limiting step in melatonin metabolism by N-acetyltransferase [14]. Also, TNFRSF13B is associated with IgA deficiency [15], FLCN is associated with renal disorder, pneumothoraces, and Birt-Hogg-Dube syndrome [16], and mutations in MYO15A cause sensorineural hearing loss (MYO15A) [17]. These genes further complicating the SMS phenotypic spectrum. Data show that phenotypes like short stature, hearing loss, speech and motor delay, hypotonia and cardiovascular anomalies are more associated with 17p11.2 deletion rather than with RAI1 mutation [3]. This suggests the presence of other genetic contributors to SMS phenotype spectrum in addition to RAI1. However, sleep disturbance, intellectual disability, and neurobehavioral features are consistent in all SMS patients, including both individuals with17p11.2 deletion and those with RAI1 mutations, indicating that RAI1 is the key gene accounting for these major phenotypes [3].

2. CIRCADIAN DEFECT IN PERSONS WITH SMS

Sleep disorder is one of the most penetrant features of SMS [18] and includes difficulties in falling asleep at night, reduced or absent rapid eye movement (REM) sleep, early waking, frequent night-time arousals, and daytime napping [18-21].

The pineal gland in human brain suprachiasmatic nucleus (SCN) controls the central circadian rhythm and melatonin secretion through light stimulation in day-night cycles. Several studies have implicated an inverted rhythm of melatonin secretion in SMS patients as the underlying cause of the sleep disturbance [19, 22]. Individuals with SMS typically have elevated melatonin secretion from the pineal gland in the daytime in contrast to very low excretion at nighttime [21-23] (Figure 2A). Studies have shown that β1-adrenergic antagonist (acetbutolol) treatment during the day may alleviate daytime melatonin peaks and improve behavior, but melatonin levels at night are not improved with acetbutolol alone [24] (Figure 2B). However, the addition of a low dose of melatonin (<3 mg) before bedtime improves the sleep time duration of SMS patients [25] (Figure 2C). Combined treatment with β-blocker (acetbutolol) to block endogenous melatonin production during the day plus exogenous melatonin administration in the evening improved the overall sleep disturbance of SMS patients and resulted in fewer daytime naps and fewer awakenings throughout the night [26-28] (Figure 2D).

The inverted secretion of melatonin, while a common finding in SMS, is not present in 100% of patients. Recent studies reported two individuals with atypical 17p11.2 deletions having normal melatonin secretion but still have sleep disturbance, included a 5 year-old female carrying a ~5 Mb deletion that extended beyond the distal SMS-REP region and a 18 year-old female carrying a ~5.8 Mb deletion that extended beyond the proximal SMS-REP region detected by high resolution CGH and FISH [14, 19]. Given that melatonin is secreted during daylight hours, its secretion is not suppressed by light in most persons with SMS. However, a pulse of bright light temporarily inhibited melatonin secretion at night for the 18 year-old female SMS patient [14], suggesting that the sleep disturbances in SMS cannot be solely attributed to the abnormal diurnal melatonin secretion versus the normal nocturnal pattern. Additionally, while Rai1-/- mice do not have melatonin, they do have circadian abnormalities [29, 30], supporting a key role for Rai1 in circadian regulation without significant melatonin impact. These facts indicate that the dysregulation of sleep is not solely due to an altered circadian secretion of melatonin. Instead, the inverted melatonin maybe a secondary effect of a dysregulated molecular circadian network, thus, influencing sleeping patterns [22].

Circadian disturbances in SMS are likely due to abnormal functioning of RAII, as SMS patients with point mutations in this gene have been reported with both sleep disturbance and altered melatonin rhythms [9]. Recent studies have shown that RAII is a critical player in maintaining the molecular clock system, both in the hypothalamus, where the suprachiasmatic nucleus (SCN) lies and is responsible for controlling the central circadian rhythm, and also within the peripheral circadian oscillators, including the liver, heart and kidney. Haploinsufficiency of RAII in SMS fibroblasts and Rai1-/- mice hypothalamic results in the dysregulation of critical genes involved in circadian biology, such as circadian locomotor output cycles kaput (CLOCK),
Table I. Clinical features of Smith-Magenis syndrome. Features are variable across the SMS population, with consistent neurobehavioral findings in all individuals.

<table>
<thead>
<tr>
<th>Sleep disturbance</th>
<th>Developmental anomalies</th>
<th>Craniofacial anomalies</th>
<th>Mid-face hypoplasia, brachycephaly, tented upper lip, micrognathia and prognathism</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurological</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>and behavioral features</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Motor aspect</td>
<td></td>
<td>Infantile hypotonia, hyporeflexia, delayed fine motor skills, sensory integration problems</td>
</tr>
<tr>
<td></td>
<td>Cognitive aspect</td>
<td></td>
<td>Mild to moderate intellectual disability, delayed speech, short-term memory impairment</td>
</tr>
<tr>
<td></td>
<td>Gait aspect</td>
<td></td>
<td>Seizures, an abnormal gait, toe walking, balance problems</td>
</tr>
<tr>
<td></td>
<td>Central nervous</td>
<td></td>
<td>Decreased gray matter in the insula and lenticular nucleolus, underdeveloped cerebellar vermis, malformed brain stem, enlarged ventricles</td>
</tr>
<tr>
<td>system defects</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Self-injurious behaviors</td>
<td></td>
<td>Skin picking, wrist biting, head banging, pulling out of nails, and insertion of objects into bodily orifices, insensitivity to pain</td>
</tr>
<tr>
<td></td>
<td>Maladaptive behaviors</td>
<td></td>
<td>Frequent outbursts, temper tantrums, attention seeking, impulsivity, aggression, disobedience, hyperactivity, attention deficits</td>
</tr>
<tr>
<td></td>
<td>Stereotypical behaviors</td>
<td></td>
<td>Spasmodic upper body squeeze, self-hugging with excitement, autistic-like behaviors, mouthing of objects, bruxism, spinning or twirling objects</td>
</tr>
<tr>
<td></td>
<td>Metabolic problems</td>
<td></td>
<td>Feeding difficulties, hypercholesterolemia, early on-set obesity, impaired satiety</td>
</tr>
</tbody>
</table>

Brain and muscle Arnt-like protein-1 (BMAL1), period circadian protein homolog genes (PER1, PER2, PER3), cryptochrome gene (CRY1, CRY2), nuclear receptor subfamily 1 group D (NR1D1, NR1D2), and RAR-related orphan receptor A genes (RORA, RORC). Functional studies have shown that RA11 siRNA knockdown in a transgenic cell line that carries the firefly luciferase gene under the control of the BMAL1 gene promoter results in a shortened period and reduced amplitude of BMAL1 expression [32]. Furthermore, ChIP-Chip and luciferase data showed that RA11 also binds to the first intron of CLOCK and positively regulate its transcriptional activity in vitro, suggesting that RA11 acts as an enhancer to bind, directly or in a complex, to the CLOCK gene, and plays an important role in the circadian loop of transcription [31].
3. SMS CIRCADIAN DEFECT INFLUENCES DEVELOPMENT, BEHAVIOR, AND METABOLISM

The outputs of endogenous circadian oscillator and melatonin secretion rhythm influence a series of physiology and development event, neurological behavior and metabolism, in response to environmental changes and physiological homeostasis [32]. Besides synthesis and release of melatonin by the pineal gland abnormally, the circadian defect in SMS might also affect the entrainment pathway (retinohypothalamic tract) and pacemaker functions (suprachiasmatic nucleus), thus further contributing the physiological processes and metabolic disturbances observed in SMS patients [28].

Many psychiatric disorders are known to involve sleep disturbance, such as autism spectrum disorder (ASD)[33], brachydactyly mental retardation syndrome (BDMR) [34], PTLS [35], Rett syndrome (RTT) [36], 2q23.1 deletion syndrome [37], fragile X syndrome [38], and Prader-Willi syndrome [39]. Several studies have shown that the severity of sleep disturbances and degree of developmental delay are proportionate to the behavior and learning problems [40-42]. Evaluation of a child with developmental delays or cognitive disability usually includes questions about sleep and napping [43]. And adverse sleep patterns often correlated to higher levels of depression and anxiety [44]. For SMS children, sleep debt, daytime melatonin secretion, and expectations from school, society and family often make them even more irritable. Stereotypical behaviors including body squeeze, self-hugging with excitement, autistic-like behaviors, and maladaptive behaviors including temper tantrums, attention seeking, aggression, and self-injurious behaviors are unique in SMS patients. Response to anxiety, in addition to insensitivity to pain, which is a consistent finding in persons with SMS, are thought to be the major contributors to the observed self-injurious behaviors [45]. Improvement of sleep quality and quantity have a direct positive effect on behavioral adherences in persons with SMS [45]. Resetting the molecular circadian network by a combined treatment with β-blocker (acetbutolol) to block endogenous melatonin production during the day plus exogenous melatonin administration in the evening improved school performance and behaviors of SMS children [24]. However, this approach has not been successful or adequate for all individuals [46], so additional treatment approaches are necessary.

Food entrained circadian rhythm also reinforces the humoral signals, such as hormones and blood glucose, and forms a feedback loop between circadian, development, metabolism, and behaviors [47]. Brain-derived neurotrophic factor (BDNF) is a growth
factor crucial for the growth of striatal neurons and is involved in several neuropsychiatric disorders like depression, schizophrenia, and obsessive-compulsive disorder. BDNF is also known to be involved in energy metabolism pathways and satiety signals [48] and is reported to be downregulated in the hypothalamus of Rai1+/− mice, which are hyperphagic, have an impaired satiety response, develop adult onset obesity, and consume more food during light phase. Rai1+/− mice also have altered fat distribution, with increased abdominal fat deposition and a reduced proportion of subcutaneous fat in females [49]. Luciferase reporter studies also showed that RAII regulates BDNF expression, via intronic enhancer elements. In vitro, RAII isoform 1 (RAIIa, long form, localized to nucleus) increased BDNF expression ~2-fold, while RAII isoform 4 (RAIIc, not localized to nucleus) does not enhance transcription [49]. Also, a study has shown that SMS mice fed a high carbohydrate diet or a high fat diet gained weight at a significantly faster rate than wild type mice and exhibited an altered fat distribution pattern. This finding suggested that mice that are haploinsufficient for Rai1 are more susceptible to diet induced obesity, and that a high fat or high carbohydrate diet may exacerbate early onset obesity outcomes in SMS patients [50]. Individuals with RAII mutations are more likely to exhibit obesity and somatic overgrowth compared to those with 17p11.2 deletions [51]. These data provide evidence that RAII is likely involved in the regulation of brain development and probably contributes to behavior, growth, and developmental problems in SMS patients.

Complicated cross-talk and feedback loops exist across circadian, behavioral, developmental and metabolic processes. For example, Rai1+/− mice exhibit altered circadian rhythm, including a shorter period and disrupted circadian rhythm, and abnormal neurological responses, such as pain insensitivity, gating problems, muscle weakness, and seizures. DfI1(17)/+ mice, with a SMS-equivalent deletion that includes Rai1, exhibit a shorter period and a dysregulated rhythm in the dark phase, similar to what was found in Rai1+/− mice [52]. Reduced expression of BDNF has been associated with obesity, hyperphagia, and behavioral abnormalities in mice and human [53, 54], similar to the phenotypes of Rai1+/− mice. Furthermore, Clock mutant mice also develop obesity [55], indicating there might be a complex feedback loop within RAII, CLOCK and BDNF, and that they may share common regulatory and downstream pathways. Among SMS patients, obesity is prevalent, starting in early adolescence and throughout adulthood; this may be due to a combination of the disrupted function of RAII and its impact on both CLOCK and BDNF.

A recent study also demonstrated that RAII, as a histone reader, recognizes a set of histone modification marks and binds histones and the nucleosome core through C-terminus PHD domain in vitro [8]. Acting as a chromatin remodeling factor, RAII may mediate interactions between chromatin, chromatin modulators, and transcriptional regulators, and regulate its downstream genes epigenetically [56]. Furthermore, histone deacetylase 4 (HDAC-4) and methyl-CpG binding domain protein 5 (MBD5) are reported to indirectly regulate RAII expression [57]. HDAC4, a histone deacetylase, acts as an eraser in histone modification, while MBD5 is a methyl-CpG binding protein and acts as a reader in DNA methylation [58]. RAII expression is reduced in cells from individuals with HDAC4 deletion or mutation [34]. Haploinsufficiency of MBD5 in both 2q23.1 deletion patient cell lines and SH-SY5Y cells causes a decrease in RAII and alters circadian gene expression, including CLOCK, PER1, PER2, PER3, NR1D2, CRY1, CRY2, RORB [37]. These data suggested RAII may have direct or indirect effects on these pathways or have multiple targets in these pathways, and likely further modulates the phenotypic spectrum of SMS through multiple genetic networks.

Gene expression microarray and pathway studies also showed that RAII acts as a transcription factor to regulate its downstream genes in several phenotype-specific biological pathways that are dysregulated in SMS. RAII gene dosage is crucial not only for normal regulation of circadian rhythm but also for neurotransmitter function and lipid metabolism, as well. Haploinsufficiency of RAII expression results in dysregulation of its downstream genes and pathways, including growth signaling and insulin sensitivity, neuronal differentiation, lipid biosynthesis and fat mobilization, circadian activity, behavior, renal, cardiovascular and skeletal development, gene expression, and cell-cycle regulation and recombination, all reflecting the spectrum of clinical features observed in SMS [59]. These dysregulated genes have been confirmed in the SMS mouse models and/or SMS patient cell lines and are potential drug targets in SMS treatments.

Since RAII is a dosage sensitive gene, and thought to function as a transcription factor and histone reader, these data imply that RAII serves as a master switch for multiple genes involved in development, neurobehavior and metabolic regulation, explaining the diverse range of symptoms seen in SMS. (Figure 3).

4. FUTURE RESEARCH AND TREATMENT OF SMS

Given the broad phenotypic spectrum of SMS, future research may identify additional genetic and environmental modifiers. Molecular cytogenetic analysis suggests that other genes in the SMS common deletion region need further investigation and may play a role in modifying circadian rhythm, cognitive development, neurobehavior, and obesity [12, 13]. As a possible contributor to neuropsychiatric disorders, RAII function in specific brain regions or different developing stages of the brain needs to be investigated. The promoter region of RAII and its regulatory sequences are not well defined; thus, elucidating its transcriptional regulators and regulatory mechanisms will help to screen drug targets for SMS. Restoring expression of both RAII and its downstream genes could rescue some of SMS phenotypes, such as sleep disturbance, cognitive function, behavioral problems, and obesity.
Early accurate diagnosis is essential for patients, families, and the society as a whole. Some SMS phenotypic features are subtle in infancy and early childhood and overlap with many other neurodevelopmental disorders like Down syndrome, Prader-Willi syndrome, Williams syndrome, Sotos syndrome, 9q34 deletion syndrome, 2q37 deletion syndrome, and Bardet-Biedl syndromes [60]. Some of the core and early onset SMS features such as craniofacial anomalies, sleep disturbance, and self-injury may help to diagnose SMS distinct from other diseases. Early intervention to address developmental delays, such as speech, motor function, and behavior and sleep management, will improve quality of life for the patient and family. Further, evaluations to assess other medical complications often associated with SMS can be targeted and addressed early before negative consequences occur.

So far, most pharmacological interventions used to alleviate the multisystem impact of SMS are not consistently effective, or many are effective only for a limited period. Elucidating pathophysiological mechanisms of this complex genetic disorder will help to provide evidence for molecular targets for pharmaceutical intervention and personalized therapeutic approaches for SMS patients.

Fig. 3. Multisystem gene network impacted in Smith-Magenis syndrome. RAI1 impacts multiple gene networks that affect the phenotypic outcomes in Smith-Magenis syndrome. Upstream transcriptional factors like HDAC4 and MBD5 are reported to indirectly affect RAI1 expression levels. RAI1 also directly regulates downstream expression of many genes, including CLOCK and BDNF. Disrupted gene expression in this network results in multiple effects, impacting circadian rhythm, metabolism, development, and neurobehavior, including inverted sleeping pattern and melatonin rhythm, hyperphagia and lack of satiety, developmental delay, and behavioral problems. The gene network analysis was generated using Cognoscente software (http://vanburenlab.medicine.tamhs.edu/cognoscente). Gray lines indicate protein:protein interactions, red arrow lines indicate protein DNA interactions, and red arrow lines indicate protein RNA interactions, genes mentioned in this paper are yellow or red squared.

REFERENCES
44. Carneiro and Araujo. The food-entrainable oscillator: a network of interconnected brain structures entrained


Conflicts of interest/Konflikt interesu
The Authors declare no conflict of interest.
Autorzy pracy nie zgłaszają konfliktu interesów.

Received/Nadesłano: 02.03.2015 r.
Accepted/Zaakceptowano: 10.03.2015 r.

Published online/Dostępne online

Address for correspondence:
Sarah H. Elsea, Ph.D, FACMG
Department of Molecular and Human Genetics
One Baylor Plaza, NAB2015
Baylor College of Medicine
Houston, TX 77030 USA
Phone: 713-798-5484
Fax: 832-825-1269
e-mail: elsea@bcm.edu